News
06-05-2012, 10:12 PM
Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.
More... (http://www.news-medical.net/news/20120606/New-immune-response-data-from-Generexe28099s-AE37-Phase-II-trial-on-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20120606/New-immune-response-data-from-Generexe28099s-AE37-Phase-II-trial-on-breast-cancer.aspx)